1. Home
  2. Analysis
  3. Symproic
  4. Paclitaxel

Symproic and Paclitaxel drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Symproic and Paclitaxel. Common interactions include ileus among females and interstitial lung disease among males.

The phase IV clinical study analyzes what interactions people who take Symproic and Paclitaxel have. It is created by eHealthMe based on reports of 33 people who take Symproic and Paclitaxel from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

33 people who take Symproic and Paclitaxel together, and have interactions are studied.

What is Symproic?

Symproic has active ingredients of naldemedine tosylate. eHealthMe is studying from 1,097 Symproic users for its effectiveness, alternative drugs and more.

What is Paclitaxel?

Paclitaxel has active ingredients of paclitaxel. It is often used in breast cancer. eHealthMe is studying from 67,559 Paclitaxel users for its effectiveness, alternative drugs and more.

Number of Symproic and Paclitaxel reports submitted per year:

Symproic and Paclitaxel drug interactions.

Common Symproic and Paclitaxel drug interactions by gender *:

female:

  1. Ileus
  2. Abdominal pain
  3. Enterocolitis
  4. Interstitial lung disease
  5. Cholangitis
  6. Decreased appetite
  7. Drug-induced liver injury
  8. Neutrophil count decreased
  9. Pulmonary tuberculosis
  10. Pyrexia

male:

  1. Interstitial lung disease
  2. Malignant neoplasm progression
  3. Tumour haemorrhage
  4. Abdominal pain
  5. Chills
  6. Diffuse alveolar damage
  7. Gastrointestinal haemorrhage
  8. Pneumonia
  9. Pyrexia
  10. Stevens-johnson syndrome

Common Symproic and Paclitaxel drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Abdominal pain
  2. Chills
  3. Hypoaesthesia
  4. Malignant neoplasm progression
  5. Pyrexia

30-39:

  1. Interstitial lung disease
  2. Malignant neoplasm progression
  3. Neutrophil count decreased
  4. Performance status decreased

40-49:

  1. Ileus
  2. Abdominal pain
  3. Enterocolitis
  4. Drug-induced liver injury
  5. Stevens-johnson syndrome
  6. Peripheral motor neuropathy
  7. Pyrexia
  8. Abdominal abscess
  9. Anorectal disorder
  10. Bladder disorder

50-59:

  1. Interstitial lung disease
  2. Malaise
  3. Nausea
  4. Rash
  5. Alopecia
  6. Bacterial infection
  7. Decreased appetite
  8. Febrile neutropenia
  9. Hyperkalaemia
  10. Hypoaesthesia

60+:

  1. Interstitial lung disease
  2. Diarrhoea
  3. Tumour haemorrhage
  4. C-reactive protein increased
  5. Cholecystitis
  6. Decreased appetite
  7. Device related infection
  8. Diffuse alveolar damage
  9. Enterococcus test positive
  10. Gastrointestinal haemorrhage

Common conditions people have *:

  1. Constipation: 16 people, 48.48%
  2. Lung Cancer - Non-Small Cell (lung cancer): 9 people, 27.27%
  3. High Blood Pressure: 7 people, 21.21%
  4. Cancer Pain: 6 people, 18.18%
  5. Pain: 5 people, 15.15%
  6. Nausea (feeling of having an urge to vomit): 4 people, 12.12%
  7. Ovarian Cancer (cancer of ovary): 4 people, 12.12%
  8. Tumor Pain: 4 people, 12.12%
  9. Peripheral Sensory Neuropathy (damage to one or more of your peripheral nerves): 3 people, 9.09%
  10. Insomnia (sleeplessness): 3 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Symproic and Paclitaxel?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Symproic and Paclitaxel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Paclitaxel side effects:

Browse all side effects of Paclitaxel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Symproic interactions:

Browse all interactions between Symproic and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Paclitaxel interactions:

Browse all interactions between Paclitaxel and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on naldemedine tosylate and paclitaxel (the active ingredients of Symproic and Paclitaxel, respectively), and Symproic and Paclitaxel (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Symproic and Paclitaxel.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.